Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label aficamten in Japanese adults with symptomatic obstructive hypertrophic cardiomyopathy
jRCT2061250024Phase 3Active, not recruiting
- Sponsor
- Bayer
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of aficamten in Hypertrophic Obstructive Cardiomyopathy (HOCM), sponsored by Bayer. Primary endpoint: Change in Valsalva LVOT-G from baseline to Week 24. Started Jun 2025; status: active, not recruiting.
02
Drugs
aficamten
03
Conditions
Hypertrophic Obstructive Cardiomyopathy (HOCM)
Beyond the preview
Go deeper on jRCT2061250024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061250024.